Study Enrollment

Your details will not be published or shared.

Clinical Trial

A Phase 3 Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease

The primary objective of this study is to evaluate the effectiveness of the study drug, GBT440 in adolescents and adults with Sickle Cell Disease (SCD) by observing the improvement of anemia. The secondary objectives are to evaluate the effects of GBT440 compared to placebo on SCD related symptoms and different clinical measures.

Eligibility Criteria

  • SIckle Cell Disease (SS or SBO-thalassemia) Age 18-65 years

Contact Information

    Leigh Wells

    (706) 721-2171